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Objective: To detect and determine disease severity of osteoarthritis (OA) using a probe activated by
matrix metalloproteinase-13 (MMP-13) in vivo in the murine destabilised medial meniscus (DMM)
surgical model of OA.
Design: We have previously described MMP12ap and MMP13ap, internally quenched ﬂuorescent peptide
substrate probes that are activated respectively by MMP-12 and MMP-13. Here we used these probes to
follow enzyme activity in vivo in mice knees 4, 6 and 8 weeks following DMM surgery. After in vivo
optical imaging, disease severity was determined through traditional histological analysis. The amount of
probe activation was analysed for discrimination between DMM, contralateral and sham operated knees,
as well as for congruence between activity and histological damage.
Results: There was no speciﬁc activation of MMP12ap at the time points observed between sham
operated and DMM operated, or their respective contralateral joints. The activation of the MMP13ap in
the DMMmodel was highest 6 weeks after surgery, but was only speciﬁc compared against sham surgery
8 weeks after surgery (1.5-fold increase). The activation of MMP13ap correlated with histological damage
6 and 8 weeks after surgery, with correlations of 0.484 (P ¼ 0.0032) and 0.478 respectively (P ¼ 0.0049).
This correlation dropped to 0.218 (P ¼ 0.011) if all data were considered.
Conclusion: The current MMP-13 activity probe is suitable for the discrimination between DMM and
sham or contralateral knees 8 weeks after surgery, when cartilage loss is typiﬁed by the appearance of
small ﬁssures up to the tidemark, but not earlier. This activity correlates with the histological damage
observed.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a multifactorial disease, which leads to the
destruction of the articular cartilage in joints and eventually the
underlying subchondral bone. The search for an effective treatment
of the disease is hampered by several factors. One of them is that
disease is followed classically by radiographical measurement of
joint space narrowing, which shows an advanced stage of tissueH. Nagase, Kennedy Institute
Headington, Oxford OX3 7FY,
. Lim), Ernst.Meinjohanns@
M. Meldal), george.gharios@
ennedy.ox.ac.uk (H. Nagase).
this work.
ternational. Published by Elsevier Ldestructionwheremost of the articulating cartilage has been lost. To
address this, increasing advances in magnetic resonance imaging
(MRI) techniques have been applied to follow cartilage degradation
in the clinic; this allowsearlier prognosis1,2. It is, however, difﬁcult to
justify this expensive imaging modality in the pre-clinical devel-
opment of drugswhere a simple, but speciﬁc biochemical biomarker
would sufﬁce. However, there is still a lack of a robust biochemical
biomarker for OA, with serum cartilage oligomeric protein levels
being one of the most widely studied3,4. Other biomarkers such as
the breakdownproducts following proteolysis of themajor cartilage
components, type II collagen and aggrecan, in blood and urine have
also been examined5. There is a clear need of both biomarkers and
non-invasive imaging methods of detecting early cartilage degra-
dation for both drug discovery and diagnosis of OA.
The proteases responsible for the degradation of cartilage
components are attractive targets for both biomarker and drugtd. All rights reserved.
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major components of cartilage are the ﬁbrillar type II collagen and
the large aggregating proteoglycan, aggrecan. Members of the
matrix metalloproteinase (MMP) and related adamalysin-like
metalloproteinase with disintegrin and thrombospondin type I
motifs (ADAMTS) family of proteases have been shown to be
involved in this degradation6. In the destabilised medial meniscus
(DMM) surgical model of OA, no degradation of aggrecan was
observed in mice lacking functional ADAMTS-5 (agrecanase-2)7,
whereas no degradation of collagen was observed in mice lacking
MMP-13 (collagenase-3)8. Mice lacking the protease cathepsin K
also showed reduced cartilage damage in surgical models of OA9.
However, it is still debatable whether this is a direct effect of
cathepsin K degradation of collagen and aggrecan, or an indirect
effect of cathepsin K upon the levels of ADAMTS-5 and MMP-13 in
the joints of these mice. The ability to monitor the activity levels of
these proteases during cartilage degradation may provide useful
biomarkers of OA.
Advances in optical imaging technologies in conjunction with
development of probes that are activated by proteases have
enabled the detection of proteolysis in vivo10. Through the reverse
design from MMP-speciﬁc inhibitors, we have developed substrate
probes that are selectively cleaved by MMP-12 (macrophage elas-
tase) andMMP-13 (collagenase 3)11. These peptide substrate probes
are ﬂanked by a near-infrared ﬂuorophore and quencher such that
upon cleavage, ﬂuorescence can be detected at tissue transparent
wavelengths. These activity probes, MMP12ap and MMP13ap, were
used to study MMP-12 and MMP-13 activity in the development of
arthritis in the collagen-induced model of murine rheumatoid
arthritis. The probes showed that MMP-12 activity was increased
early during inﬂammation where macrophage inﬁltration is
observed whereas MMP-13 activity was detected later during joint
destruction.
Here we test the use of the MMP12ap and MMP13ap to detect
and follow OA disease progression in the DMMmodel of OA. Given
the smaller role of inﬂammation in the DMMcompared to collagen-
induced arthritis, we hypothesised that there would be lesser
activation ofMMP12ap compared with toMMP13ap. If the MMP-13
activity probewas successful in detecting and following OA disease,
it would be a useful tool during the development of disease
modifying drugs and the early detection of OA.
Methods
Probes
TheMMP12ap (QSY-21-GPLGwLEEAK(Cy5.5)G-OH) andMMP13ap
(QSY-21-GGPAGwLYEK(Cy5.5)G-OH) probes were prepared and
characterized as previously described11.
Animal models
Male C57 BL/6J mice aged 10weeks were purchased fromHarlan
Laboratories (Blackthorn, Bicester, UK). Micewere housed in groups
of 6 in individually vented cages, maintained at 21  2C on a 12-
h light/dark cycle and with food and water provided ad libitum. All
experimental protocols were performed in compliance with the UK
Animals (Scientiﬁc Procedures) Act 1986 regulations for the
handling and use of laboratory animals (Home Ofﬁce project
licence PPL no: 70/6537).
The DMM surgery was performed on 10-week-old male mice as
described previously12. Brieﬂy, following induction of anaesthesia
by injection of 10 ml/g of Hypnorm/Hypnovel (at a ratio of 1:1e4
parts water), the right knee joint was accessed via amedial incision.
The right meniscotibial ligament was transected, resulting in therelease of the medial meniscus from its tibial attachment. Sham
surgery consisted of medial capsulotomy of the right knee. All an-
imals received buprenorphine HCl (Vetergesic; Alstoe Animal
Health, York, UK) delivered sub-cutaneously immediately post
surgery. A total of 82 animals were used (divided equally into DMM
and sham surgeries, 36 for the MMP12ap probe and 46 for the
MMP13ap probe). Recovery from surgery was monitored daily by
weight, visual inspection of wound healing and behaviour for two
weeks. There was no difference in weight gain between groups
observed throughout the experiment.
Activation of probes in vivo
Four, 6 and 8 weeks after surgery, 150 ml of 1 mM MMP-12ap or
MMP-13ap was delivered intravenously via the tail vein. Two, 4 and
8 h after injection, consecutive ﬂuorescence images were obtained
by exposing mice under gaseous anaesthesia (2.5% (v/v) isoﬂurane
and O2) in a Kodak In vivo FX Pro (Carestream,Woodbridge, USA), to
a 630 nm excitation and capturing emission at 700 nm for 1 min.
X-ray images were taken at the same time point for co-registration
of signal to the knee joint, by exposure to X-rays for 20 s.
Image analysis
Fluorescence images were analysed using the Carestream MI
software (version 5.1, Carestream, Woodbridge, USA). Regions of
interest (ROI) were deﬁned as a circle of 65 pixels for knees. The ROI
for knees was centred in the joint space as visualised using co-
registered X-ray images. The mean ﬂuorescent intensity (MFI) of
the ROI was then obtained. No background intensity was subtracted
from the values.
Histology and scoring of cartilage damage
After images at the 8 h time points were taken, mice were
sacriﬁced by cervical dislocation and the knee joints were dissected
and ﬁxed in formalin (2% (v/v)) overnight, decalciﬁed in ethylene
diamine tetra acetic acid (EDTA) for 5 weeks and embedded in
parafﬁn. Serial sections 5 mm in thickness were cut. Every tenth
section was stained with Safranin O for scoring cartilage damage.
Scoring of the extent of cartilage damage in individual sections was
done in accordance with the guidelines laid out in the OARSI his-
topathology initiative for small animals on a scale from 1 to 6 by
two different observers13. All four quadrants of the section (medial
tibial plateau, lateral tibial plateau, medial femoral condyle, lateral
femoral condyle) are scored individually and added for each his-
tological section. The scores of the top three adjoining sections are
added together to give the summed score (for a maximal score 72).
Statistical analysis
All statistical analysis were performed with the software Prism
(version 5.0, GraphPad Software, La Jolla, USA). Twoway analysis of
variance (ANOVA) withmatched values and Bonferonni’s post-tests
were used to analyse the data in Figs. 3 and 4(A), paired Student’s
t-tests were used to analyse the data in Fig. 4(B) and Pearson’s
correlation without correction was used to analyse the data in
Fig. 5(B)e(D).
Results
Progression of OA in the DMM model of OA
Histological analysis indicated that there was signiﬁcantly
increased damage observed in the DMM animals from 4 weeks
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Fig. 1. Histological progression of DMM in this study. Typical histological sections of the DMM operated right knee joints stained with Safranin O obtained at (A) 4 weeks, (B) 6
weeks and (C) 8 weeks after surgery. Damaged areas within cartilage sections are indicated with arrows. (D) Summed histological scores obtained from addition of the scores of the
top 3 consecutive scoring slides per knee. Data are mean  95% CI.
N.H. Lim et al. / Osteoarthritis and Cartilage 22 (2014) 862e868864after surgery, which increased further at 6 and 8 weeks after sur-
gery [Fig. 1]. These changes are comparable to those observed in
DMM surgery performed elsewhere12,14.
Probes in the DMM model of OA
Co-registered X-ray images were used to deﬁne the ROI of the
knee joint in the ﬂuorescent images. The 65-pixel circular ROI used
is marked in the X-ray images in Fig. 2. Typical ﬂuorescence images
obtained using MMP12ap and MMP13ap are also shown in Fig. 2.
The amount of signal obtained from the knees using both probes
was between 200 and 2000 mean ﬂuorescence units. This was
lower than the signal which we obtained using the probes in
collagen induced arthritis11.
Therewas no signiﬁcant difference in the activation ofMMP12ap
between DMM operated knees and control knees at any of the time
points observed [Fig. 3, (n) ¼ 6 in each group]. The non-disease-
speciﬁc activation of MMP12ap was highest at 4 weeks and
decreased as time progressed in all groups of animals. ThisWeek 4
Week 6
Week 8 
DMM
LK RK
Sham Sham
MMP1X-Ray
Fig. 2. Representative images obtained 4 h following intravenous injection of MMP12ap an
images obtained 4 h following intravenous injection of either 150 ml of 1 mM MMP12ap or M
(RK) and the red circle marking the ROI used for analysis are indicated. The ﬂuorescence ractivation of MMP12ap is therefore most likely due to processes
involved in the repair of the capsule of the knee joint in both DMM
and sham surgeries.
Activation ofMMP13apwas different fromMMP12ap during the
course of DMM. At the earliest time point, 4 weeks after surgery,
there was no signiﬁcant difference in probe activation between any
of the groups at the 2, 4 and 8 h time points [Fig. 4(A), top]. This was
also reﬂected when the signal difference between the operated and
contralateral knee was calculated [Fig. 4(B), top]. Six weeks after
surgery, there was signiﬁcant difference in the amount of activated
probe detected between the DMM operated and its contralateral
knees at the 2 h time point according to two-way ANOVA, but no
signiﬁcant difference between DMM operated and sham operated
knees at any of the other time points [Fig. 4(A), middle]. Further-
more, at 6 weeks, there was signiﬁcant average difference of 400e
600 units in the signal obtained from the DMM operated and its
contralateral knees, whereas there was no difference between the
sham operated and its contralateral knees [Fig. 4(B), middle]. Eight
weeks after surgery there was signiﬁcant difference between theDMM
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Fig. 3. Quantiﬁcation of the activation ofMMP12ap in the DMMmodel of OA.Mice were
injected with 150 ml of 1 mM of MM12ap intravenously 4, 6 and 8 weeks after DMM or
sham surgery. Images were taken 2, 4 and 8 h after injection and used to quantify the
MFI in the operated and contralateral knees. Whiskers depict the 95% CI. n ¼ 6 for each
group. Analysis by two-way ANOVAwith Bonferroni post-tests indicated no signiﬁcant
difference between any of the groups at any time points between the weeks.
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either the contralateral knee or the sham operated knees 4 h after
the injection of probe [Fig. 4(A), bottom]. The signiﬁcant average
difference in signal between the operated and contralateral knees
of the DMM operated animals was between 150 and 230 units
throughout the time course [Fig. 4(B), bottom].
The earliest time at which MMP13ap could reliably distinguish
the DMM operated knee from contralateral or sham operated knees
was 8 weeks after surgery, with a 1.5-fold higher signal in the DMM
knees compared to the controls. Earlier, at 6 weeks, the probe could
differentiate between operated and contralateral knees only if it
was known a priori that DMM surgery had been performed. The
amount ofMMP13ap activation detected was highest 6 weeks after
surgery [Fig. 5(A)], indicating that the peak of detected MMP-13
activity occurred before the rise in histological damage. We have
then examined whether there was any signiﬁcant correlation be-
tween the activation of MMP13ap and histological damage in the
knee joints, regardless if this damage was in the DMM, sham or
contralateral groups. We found that there was no signiﬁcant cor-
relation between the activation of MMP13ap and histological
damage 4weeks after surgery [Fig. 5(B), (r)¼ 0.26, P¼ 0.22, n¼ 24].
However, there was signiﬁcant correlation between activation of
MMP13ap and histological damage separately at 6 and 8 weeks
[Fig. 5(C) and (D)], with a correlation, r, of 0.484 (P¼ 0.0032, n¼ 36)
and 0.478 (P ¼ 0.0049, n ¼ 32) respectively. In addition, when all
the data was combined, there was weak but signiﬁcant correlation
between the activation of MMP13ap and histological disease score
throughout the time period studied (r ¼ 0.263, P ¼ 0.011, n ¼ 92).
This indicates that histological tissue damage correlates with the
activity of MMP-13 in the cartilage.
Discussion
We have used two previously described activity probes for
MMP-12 and MMP-13,MMP12ap andMMP13ap respectively, in the
DMMmodel of murine OA to determine their utility in both disease
diagnosis and disease severity. Inﬂammation plays a smaller role in
the DMM model of OA, compared to the collagen-induced arthritis
model of rheumatoid arthritis and this is reﬂected in the data ob-
tained from MMP12ap. The lack of difference between the activa-
tion ofMMP12ap in the DMM and sham operated groups of animals
indicated there is no signiﬁcant involvement of macrophage
migration in the disease process at least at 4e8 weeks after the
operation. The activation of MMP13ap however, discriminated be-
tween the DMM and controls 8 weeks after surgery, when cartilage
damage is exempliﬁed by small ﬁssure(s) extending to the tidemark
of calciﬁed cartilage. This represents a relatively early stage in the
degeneration of the type II collagen ﬁbrils. The activation of
MMP13ap also correlated with histological damage separately at 6
and 8 weeks after surgery, but this correlation weakened when
combined, due to the higher levels of MMP13ap activation at 6
weeks. This indicates that there may be a peak in MMP-13 activity,
and that damage to the tissue past a certain point is reliant on other
factors, such as mechanical wear. This work represents the ﬁrst in-
depth study linking detectable in vivo MMP-13 activity from joints
with OA disease progression.
While theMMP13ap probe is capable of differentiating between
DMM and sham surgeries in this study, it is currently unsuitable as
a biomarker for OA disease, owing to the weak overall correlation
between probe activation and histological damage. Other studies
using peptide substrate probes to detect MMP-13 activity in OA
joints have focused on intra-articular delivery of the probe in rats15.
Intra-articular delivery is suitable for studies using surgical models
of OA, as the timing and joint location of disease occurrence is
known. However, for models of spontaneous OA16, such as those
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Fig. 4. Quantiﬁcation of the activation of MMP13ap in the DMM model of OA mice were injected with 150 ml of 1 mM of the MMP13ap intravenously 4, 6 and 8 weeks after DMM or
sham surgery. Images were taken 2, 4 and 8 h after injection and used to quantify the MFI in the operated and contralateral knees (A). Whiskers depict the 95% ci. n ¼ 6 for each
group in week 4, n ¼ 9 for each group in week 6 and n ¼ 8 for each group in week 8. *P < 0.05 between DMM and other groups after two-way ANOVA analysis with Bonferroni post
tests (DMM vs contra: P ¼ 0.0477, DMM vs Sham: P ¼ 0.0421, DMM vs Sham contra: P ¼ 0.0161). (B) The difference in signal between the operated and contralateral knees in the
DMM and sham groups. *P < 0.05 by paired Student’s t test, individual values as indicated.
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DuncaneHartley guinea pigs, the ability to deliver probes intrave-
nously becomes essential due to the unknown in both time and
joint(s) affected. We have used this delivery route in this study with
promising results. Improvements to the peptide probe described
here, such as increased speciﬁcity, increased rate of cleavage by
MMP-13 and increased retention in joint/cartilage, needs to be
explored in order to realise its potential as a biomarker for OA
disease progression.
Apart from mice deﬁcient in MMP-13, mice deﬁcient in
ADAMTS-5 are protected in the DMM model7,8. An ADAMTS-5 ac-
tivity probe may potentially serve as an earlier marker for OA, as
aggrecan degradation is thought to occur before collagendegradation17. There is, however, a higher turnover of aggrecan in
normal tissue compared to collagen18,19, which may make it difﬁ-
cult to differentiate the normal vs the pathological activity, limiting
the utility of such an in vivo ADAMTS-5 probe.
Speciﬁc inhibitors for both ADAMTS-5 and MMP-13 are in
development. Commonly used animal OA models in which the ef-
ﬁcacies of these inhibitors are tested are those of the DMM or the
anterior cruciate ligament injury model20. These models are well
characterised in terms of where and when disease develops and
how fast it progresses. Disease progression in human OA is
currently unpredictable and the relative contributions of these
proteolytic enzymes during this progression is not clear. Probes
capable of detecting speciﬁc enzyme activity will allow us to start
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Fig. 5. Longitudinal correlation of the signal from the MMP13ap in the progression of
the DMM model of OA The MFI of the relevant ROIs obtained at 4 h after injection of
the MMP13ap was plotted against either the duration after surgery (A) or the indi-
vidual summed histological scores 4 weeks (B), 6 weeks (C) or 8 weeks (D) after
surgery. *P < 0.05 between DMM and other groups, as detailed in Fig. 4. The Pearson
correlation factor, r at P < 0.005, between mean ﬂuorescent signal and histological
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N.H. Lim et al. / Osteoarthritis and Cartilage 22 (2014) 862e868 867to address this. Additionally, they may provide time frames where
particular inhibitor therapies, should be prescribed, as theremay be
a window where an ADAMTS-5 inhibitor will be effective and a
different window where an MMP-13 inhibitor would be. Thus,
concurrent development of ADAMTS-5 andMMP-13 activity probes
and their use may guide future management of clinical OA.
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